Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Repare Therapeutics Inc. | rptx-ex322_7.htm |
| EX-31.2 - EX-31.2 - Repare Therapeutics Inc. | rptx-ex312_6.htm |
| EX-31.1 - EX-31.1 - Repare Therapeutics Inc. | rptx-ex311_9.htm |
| EX-10.2 - EX-10.2 - Repare Therapeutics Inc. | rptx-ex102_209.htm |
| EX-10.1 - EX-10.1 - Repare Therapeutics Inc. | rptx-ex101_111.htm |
| 10-Q - 10-Q - Repare Therapeutics Inc. | rptx-10q_20200930.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Repare Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Lloyd M. Segal, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: November 12, 2020 |
|
/s/ Lloyd M. Segal |
|
|
|
Lloyd M. Segal |
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |
1